The Financial Times - February 17, 2011
Astellas has signed an agreement with the American Aveo Pharmaceuticals for $ 1.4 billion and expand the market of oncology. develop and market in EU and North America tivozanib, experimental treatment for kidney cancer, in breast, lung and colon-rectum and will equally share profits . Astellas will pay $ 125 million immediately and 1 billion later, the Payment of the remaining 275 million will depend on the achievement of objectives.
0 comments:
Post a Comment